2024
Acute pancreatitis: pathogenesis and emerging therapies
Zaman S, Gorelick F. Acute pancreatitis: pathogenesis and emerging therapies. Journal Of Pancreatology 2024, 7: 10-20. PMID: 38524855, PMCID: PMC10959536, DOI: 10.1097/jp9.0000000000000168.Peer-Reviewed Original ResearchAcute pancreatitisSevere inflammatory disordersLimited treatment optionsLong-term outcomesPotential treatment benefitsPromising new therapyDisease mechanismsPotential therapeutic targetEmerging TherapiesAcute injuryInflammatory disordersPharmacologic interventionsTreatment optionsTreatment benefitPotential therapyNew therapiesSpecific treatmentTherapeutic targetNew treatmentsTherapyPancreatitisTreatmentComplicationsPathogenesisInjury
2018
T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer
Chobrutskiy BI, Zaman S, Diviney A, Mihyu MM, Blanck G. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer. Journal Of Cancer Research And Clinical Oncology 2018, 145: 615-623. PMID: 30539280, DOI: 10.1007/s00432-018-2815-1.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesT cell responsesBladder tumor tissuesT-cell featuresEx vivo amplificationT cell receptorBladder cancerCancer findingsFavorable outcomeCancer settingBetter outcomesSurvival rateTumor tissueCancerDriver mutationsImmunotherapyBiochemical featuresBioinformatics assessmentOutcomesAntigen bindingRegion 3TILsPatientsLymphocytesTherapyClinical Observation of Improved Outcomes of Patients With BRCA 1/2 Breast Cancer Treated With Everolimus Prior to DNA-Damaging Therapy.
Anderson M, Denson A, Zaman S, Han H, Soliman H. Clinical Observation of Improved Outcomes of Patients With BRCA 1/2 Breast Cancer Treated With Everolimus Prior to DNA-Damaging Therapy. JCO Precision Oncology 2018, 2: 1-5. PMID: 35135142, DOI: 10.1200/po.18.00123.Peer-Reviewed Original Research